Life Medicine

Life Medicine is a fully open-access bimonthly journal founded in 2022 and published by Higher Education Press with Oxford University Press, covering basic and translational biomedical research, with a 2025 Journal Impact Factor of 7.7 and a first-quartile rank of 29 of 191 in research and experimental medicine《生命医学》（Life Medicine）是 2022 年创办的全开放获取双月刊，由（Higher Education Press）与（Oxford University Press）联合出版，覆盖基础医学与转化医学研究，2025 年影响因子为 7.7，在研究性与实验医学类 191 种期刊中列第 29 位，居第一四分位。

Scope

• Life science and health science form the base of the journal's remit, with an emphasis on mechanistic insight that can be carried toward clinical use生命科学与健康科学构成该刊的基础范围，强调可向临床应用推进的机制性认识。
• Intelligent medicine is a named area, covering computational and data-driven approaches to disease understanding, diagnosis and treatment智能医学是明确列出的方向，涵盖以计算与数据驱动方式理解、诊断和治疗疾病的研究。
• Reproductive medicine, geriatric medicine and regenerative medicine are treated as connected fields rather than separate specialties生殖医学、老年医学与再生医学被视为相互关联的领域，而非彼此割裂的专科。
• Pharmacology and genetic disease are within scope, including work on drug action, inherited disorders and their models药理学与遗传性疾病属于收稿范围，包括药物作用、遗传病及其模型研究。
• Infectious, cardiovascular, respiratory, digestive, neurological and immunological disorders are all listed among current areas of interest感染性、心血管、呼吸、消化、神经与免疫系统疾病均被列为当前关注的方向。
• Article types include Articles, Resources, Reviews, Letters, Previews, Research Highlights, News and Opinions and Forums, many of them commissioned文章类型包括原创论文、资源类论文、综述、快报、预览、研究亮点、新闻与观点以及论坛，其中不少为约稿。

History

• The journal was launched in 2022 by Higher Education Press, China's largest education publisher, which had been building a portfolio of English-language life science titles该刊 2022 年由（Higher Education Press）创办，这家中国最大的教育类出版社此前已在建设英文生命科学期刊群。
• Oxford University Press took over international distribution and hosting from January 2023, and the title now appears on the Oxford Academic platform（Oxford University Press）自 2023 年 1 月起负责其国际发行与平台托管，该刊现于（Oxford Academic）平台出版。
• Academic support comes from the Institute of Zoology of the Chinese Academy of Sciences and the Beijing Institute for Stem Cell and Regenerative Medicine该刊的学术支持来自中国科学院动物研究所与北京干细胞与再生医学研究院。
• It is fully open access under a Creative Commons Attribution licence and charges no article processing fee, a policy recorded in the Directory of Open Access Journals该刊采用知识共享署名许可的全开放获取模式，不收取文章处理费，这一政策已载入（DOAJ）记录。
• It is indexed in ESCI, PubMed Central, Scopus, DOAJ, CAS, Biological Abstracts and BIOSIS Previews, and its Journal Impact Factor rose from 6.0 in 2024 to 7.7 in 2025该刊被（ESCI）、（PubMed Central）、（Scopus）、（DOAJ）、（CAS）、（Biological Abstracts）与（BIOSIS Previews）收录，影响因子由 2024 年的 6.0 升至 2025 年的 7.7。

Editors

• The editor-in-chief is Guang-Hui Liu of the Institute of Zoology, Chinese Academy of Sciences, whose work focuses on stem cell biology and ageing主编为中国科学院动物研究所的（Guang-Hui Liu），其研究聚焦干细胞生物学与衰老。
• Juan Carlos Izpisua Belmonte serves as co-editor-in-chief, bringing expertise in developmental biology and regenerative medicine from the Salk Institute and later Altos Labs（Juan Carlos Izpisua Belmonte）任共同主编，其在（Salk Institute）及此后在（Altos Labs）的工作为期刊带来发育生物学与再生医学方面的专长。
• The editorial team is international and draws on both Chinese and overseas laboratories, matching the journal's bench-to-bedside mandate编辑团队具有国际性，同时依托中国与海外实验室，与该刊从实验台到病床的办刊宗旨相称。
• Peer review is single anonymous, with reviewers aware of author identities but not identified in the reports sent back该刊采用单匿名同行评审，审稿人知晓作者身份，但反馈给作者的评审意见不披露审稿人信息。
• Authors are not charged for publication, and the journal reports an average of about nine weeks from submission to publication作者无需支付出版费用，该刊公布的平均周期为自投稿至发表约九周。
• Manuscripts are submitted through the Oxford Academic system, and the journal publishes continuously online while collecting articles into bimonthly issues稿件通过（Oxford Academic）系统投递，该刊先在线连续发表，再按双月刊汇编成期。